Ozempic and Wegovy are making so much money for Novo Nordisk A/S that their cumulative sales will soon surpass the ...

Novo Nordisk, tje manufacturer behind Ozempic and Wegovy has another weight loss medication in the works — but according to ...

Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...

Novo Nordisk's U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm’s latest obesity treatment ...

By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -Novo Nordisk's shares fell nearly 5% on Friday after ...

Novo Nordisk said European regulators support the use of its blockbuster weight-loss drug Wegovy to help reduce heart failure ...

The European Medicines Agency backed the use of Novo Nordisk's popular drug Wegovy to help ease heart failure in people with ...

Novo Nordisk’s obesity drug Wegovy is now recommended by EU regulatory authorities for obesity-related heart conditions.

Novo Nordisk A/S’s obesity shot Wegovy also prevents strokes, heart attacks and death. The price of those benefits is far ...

Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart ...

Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.

NVO stock gains 4.2% after it presents efficacy data superior to Wegovy for its new oral pill, amycretin, in an early-stage ...